According to the AASLD webcast, ASMB thinks HBsAg has little if any consequence as a predictor of a complete response (i.e. cure) to chronic HBV
Roche and JNJ probably don't agree with this assertion as the rich deals they struck to get RNAi drugs for hep b is probably because of the ability of the drugs to lower HBsAg